These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1243 related items for PubMed ID: 19243709

  • 1. The effect of pramipexole on mood and motivational symptoms in Parkinson's disease: a meta-analysis of placebo-controlled studies.
    Leentjens AF, Koester J, Fruh B, Shephard DT, Barone P, Houben JJ.
    Clin Ther; 2009 Jan; 31(1):89-98. PubMed ID: 19243709
    [Abstract] [Full Text] [Related]

  • 2. Long-term effect of initiating pramipexole vs levodopa in early Parkinson disease.
    Parkinson Study Group CALM Cohort InvestigatorsDepartment of Neurology, University of Rochester, 1351 Mt Hope Ave, Ste 220, Rochester, NY 14620, USA. kevin.biglan@ctcc.rochester.edu.
    Arch Neurol; 2009 May; 66(5):563-70. PubMed ID: 19433655
    [Abstract] [Full Text] [Related]

  • 3. Pramipexole for the treatment of depressive symptoms in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled trial.
    Barone P, Poewe W, Albrecht S, Debieuvre C, Massey D, Rascol O, Tolosa E, Weintraub D.
    Lancet Neurol; 2010 Jun; 9(6):573-80. PubMed ID: 20452823
    [Abstract] [Full Text] [Related]

  • 4. Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial.
    Holloway RG, Shoulson I, Fahn S, Kieburtz K, Lang A, Marek K, McDermott M, Seibyl J, Weiner W, Musch B, Kamp C, Welsh M, Shinaman A, Pahwa R, Barclay L, Hubble J, LeWitt P, Miyasaki J, Suchowersky O, Stacy M, Russell DS, Ford B, Hammerstad J, Riley D, Standaert D, Wooten F, Factor S, Jankovic J, Atassi F, Kurlan R, Panisset M, Rajput A, Rodnitzky R, Shults C, Petsinger G, Waters C, Pfeiffer R, Biglan K, Borchert L, Montgomery A, Sutherland L, Weeks C, DeAngelis M, Sime E, Wood S, Pantella C, Harrigan M, Fussell B, Dillon S, Alexander-Brown B, Rainey P, Tennis M, Rost-Ruffner E, Brown D, Evans S, Berry D, Hall J, Shirley T, Dobson J, Fontaine D, Pfeiffer B, Brocht A, Bennett S, Daigneault S, Hodgeman K, O'Connell C, Ross T, Richard K, Watts A, Parkinson Study Group.
    Arch Neurol; 2004 Jul; 61(7):1044-53. PubMed ID: 15262734
    [Abstract] [Full Text] [Related]

  • 5. Randomized, double-blind, multicenter evaluation of pramipexole extended release once daily in early Parkinson's disease.
    Hauser RA, Schapira AH, Rascol O, Barone P, Mizuno Y, Salin L, Haaksma M, Juhel N, Poewe W.
    Mov Disord; 2010 Nov 15; 25(15):2542-9. PubMed ID: 20669317
    [Abstract] [Full Text] [Related]

  • 6. Long-term efficacy and safety of pramipexole in advanced Parkinson's disease: results from a European multicenter trial.
    Möller JC, Oertel WH, Köster J, Pezzoli G, Provinciali L.
    Mov Disord; 2005 May 15; 20(5):602-10. PubMed ID: 15726540
    [Abstract] [Full Text] [Related]

  • 7. Extended-release pramipexole in early Parkinson disease: a 33-week randomized controlled trial.
    Poewe W, Rascol O, Barone P, Hauser RA, Mizuno Y, Haaksma M, Salin L, Juhel N, Schapira AH, Pramipexole ER Studies Group.
    Neurology; 2011 Aug 23; 77(8):759-66. PubMed ID: 21832218
    [Abstract] [Full Text] [Related]

  • 8. Increase in body weight after pramipexole treatment in Parkinson's disease.
    Kumru H, Santamaria J, Valldeoriola F, Marti MJ, Tolosa E.
    Mov Disord; 2006 Nov 23; 21(11):1972-4. PubMed ID: 16972276
    [Abstract] [Full Text] [Related]

  • 9. Adding a dopamine agonist to preexisting levodopa therapy vs. levodopa therapy alone in advanced Parkinson's disease: a meta analysis.
    Talati R, Baker WL, Patel AA, Reinhart K, Coleman CI.
    Int J Clin Pract; 2009 Apr 23; 63(4):613-23. PubMed ID: 19222614
    [Abstract] [Full Text] [Related]

  • 10. A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study.
    Parkinson Study Group.
    Arch Neurol; 2005 Feb 23; 62(2):241-8. PubMed ID: 15710852
    [Abstract] [Full Text] [Related]

  • 11. Double-blind, single-dose, cross-over study of the effects of pramipexole, pergolide, and placebo on rest tremor and UPDRS part III in Parkinson's disease.
    Navan P, Findley LJ, Jeffs JA, Pearce RK, Bain PG.
    Mov Disord; 2003 Feb 23; 18(2):176-80. PubMed ID: 12539211
    [Abstract] [Full Text] [Related]

  • 12. Pharmacologic treatment of advanced Parkinson's disease: a meta-analysis of COMT inhibitors and MAO-B inhibitors.
    Talati R, Reinhart K, Baker W, White CM, Coleman CI.
    Parkinsonism Relat Disord; 2009 Aug 23; 15(7):500-5. PubMed ID: 19167259
    [Abstract] [Full Text] [Related]

  • 13. Sarizotan as a treatment for dyskinesias in Parkinson's disease: a double-blind placebo-controlled trial.
    Goetz CG, Damier P, Hicking C, Laska E, Müller T, Olanow CW, Rascol O, Russ H.
    Mov Disord; 2007 Jan 15; 22(2):179-86. PubMed ID: 17094088
    [Abstract] [Full Text] [Related]

  • 14. Conversion from dopamine agonists to pramipexole. An open-label trial in 227 patients with advanced Parkinson's disease.
    Linazasoro G, Spanish Dopamine Agonists Study Group.
    J Neurol; 2004 Mar 15; 251(3):335-9. PubMed ID: 15015015
    [Abstract] [Full Text] [Related]

  • 15. Twice-daily, low-dose pramipexole in early Parkinson's disease: a randomized, placebo-controlled trial.
    Kieburtz K, Parkinson Study Group PramiBID Investigators.
    Mov Disord; 2011 Jan 15; 26(1):37-44. PubMed ID: 20925067
    [Abstract] [Full Text] [Related]

  • 16. Pramipexole, a nonergot dopamine agonist, is effective against rest tremor in intermediate to advanced Parkinson's disease.
    Künig G, Pogarell O, Möller JC, Delf M, Oertel WH.
    Clin Neuropharmacol; 1999 Jan 15; 22(5):301-5. PubMed ID: 10516884
    [Abstract] [Full Text] [Related]

  • 17. Rationale for delayed-start study of pramipexole in Parkinson's disease: the PROUD study.
    Schapira AH, Albrecht S, Barone P, Comella CL, McDermott MP, Mizuno Y, Poewe W, Rascol O, Marek K.
    Mov Disord; 2010 Aug 15; 25(11):1627-32. PubMed ID: 20544810
    [Abstract] [Full Text] [Related]

  • 18. Testosterone therapy in men with Parkinson disease: results of the TEST-PD Study.
    Okun MS, Fernandez HH, Rodriguez RL, Romrell J, Suelter M, Munson S, Louis ED, Mulligan T, Foster PS, Shenal BV, Armaghani SJ, Jacobson C, Wu S, Crucian G.
    Arch Neurol; 2006 May 15; 63(5):729-35. PubMed ID: 16682542
    [Abstract] [Full Text] [Related]

  • 19. Early piribedil monotherapy of Parkinson's disease: A planned seven-month report of the REGAIN study.
    Rascol O, Dubois B, Caldas AC, Senn S, Del Signore S, Lees A, Parkinson REGAIN Study Group.
    Mov Disord; 2006 Dec 15; 21(12):2110-5. PubMed ID: 17013922
    [Abstract] [Full Text] [Related]

  • 20. The effect of pramipexole on depressive symptoms in Parkinson's disease.
    Yasui N, Sekiguchi K, Hamaguchi H, Kanda F.
    Kobe J Med Sci; 2011 Feb 02; 56(5):E214-9. PubMed ID: 21937869
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 63.